CSI Market
Sign In | Register

Aridis Pharmaceuticals Inc (ARDS) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ARDS quarterly Cash Flow →
The quarterly cash flow data below helps track how Aridis Pharmaceuticals Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Dec 31 2021) (Dec 31 2020) (Dec 31 2019) (Dec 31 2017)
Operating Activities
Income-30.37
Depreciation & amortization0.49
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.23
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.48
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Income Loss From Equity Method Investments Exclude Joint Venture-
Issuance Of Common Stock In Connection With License Agreement Operating Activities-
Non Cash Debt Issuance Expense-
Change In Fair Value Of Note Payable0.35
Increase Decrease In Contract With Customer Asset-
Issuance Of Common Stock In Connection With License Agreement-
Issuance Of Common Stock In Exchange For Debt Modification-0.84
Increase Decrease In Operating Lease Liabilities-0.03
Increase Decrease In Contract With Customer Liability-0.84
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-1.00
Increase (Decrease) in Accounts Payable-2.93
Increase (Decrease) in Accrued Liabilities3.19
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.21
Other Working Capital0.10
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.84
Discontinued operations0.00
Net Cash flow from Operating Activities-29.13
Investing Activities
Capital Expenditures-0.08
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.08
Financing Activities
Short-term debt Net5.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1.80
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-7.37
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents19.99
Payment On Financing Of Insurance Premium-
Proceeds From Financing Of Insurance Premium-
Payments On Financing Of Insurance Premium-1.03
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities14.78
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-29.21
Total Cash Flow-14.43
4 historic quarters locked

Sign in to unlock the full Aridis Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Aridis Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-23-039521

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License